(Note: Advaxis, Inc. withdrew its plan for a NASDAQ uplisting – a unit offering of stock and warrants – in an SEC filing dated June 27, 2022. The company did not intend to list the warrants on the NASDAQ. Advaxis filed an S-1 on May 12, 2022, for the public offering in connection with the NASDAQ uplisting of its stock from the OTCQX. The public offering price of $3.70 was the last reported sale of its common stock on the OTCQX Best Market under the symbol “ADXSD” as of June 8, 2022. **The board of directors approved a reverse stock split at a ratio of one-for-80, which took effect on June 6, 2022.)

We are a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen-presenting cells (“APCs”) to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor micro-environment, or TME, to enable the T cells to attack tumor cells.

We believe that its current pipeline evaluating off-the shelf, neoantigen-directed immunotherapies (i.e., our HOT program) can address significant unmet needs in the current oncology treatment landscape. Specifically, our first drug construct from the HOT program is ADXS-503 (HOT Lung), which has been designed to treat non-small cell lung cancer (NSCLC); it has the potential to optimize checkpoint inhibitors’ performance in NSCLC, while having a generally well-tolerated safety profile.

On July 15, 2021, the Company announced the initiation of a Phase 1 clinical study evaluating the second drug construct from our HOT program, ADXS-504 (HOT Prostate), in patients with biochemically recurrent prostate cancer. The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504 for the treatment of early prostate cancer.